Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/12/18 (What's New)

Summary

  • SWITCHMRK 032 and 033 studies evaluated virologically suppressed patients stable on lopinavir/ritonavir-based antiretroviral therapy with ≥ 2 NRTIs who were switched to raltegravir or continued their original regimen[Eron 2010]
    • Both studies were stopped prematurely because at Week 24 raltegravir failed to meet the protocol-defined criteria for noninferiority
  • SPIRAL study, which randomized patients suppressed on boosted-PI regimens to switch to raltegravir or continue their boosted PI, did not report an increased risk of virologic failure in the switch arm,[Martínez 2010] even in patients who had experienced previous virologic failure

Action required

Keywords: Switch Strategies

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.